EGFR and neoplasm: The measurement of the CEA tumor marker is convenient and noninvasive, and it could be a good surrogate predictive marker of disease progression and survival outcomes in patients with mCRC treated with first-line systemic chemotherapy alone or combination with anti-EGFR mAb, whereas it is less effective in those treated with anti-VEGF mAb.